FDA's new Artificial Intelligence-Enabled Device Software Functions guidance reflects this modernized philosophy. It introduces a Total Product Lifecycle (TPLC) framework tailored to AI, placing continuous accountability at the center of regulatory expectations. Developers are now encouraged – and increasingly expected – to articulate model architecture transparently, validate performance and safety across representative populations, address bias upfront, and establish robust post-market performance monitoring to identify issues such as drift. These expectations signal an understanding that AI is not static; instead, it is an evolving clinical partner that must be overseen dynamically.

Simultaneously, FDA is opening the door wider for responsible acceleration. Updated guidance documents for low-risk AI tools and certain clinical decision support (CDS) functions create broader defined pathways to allow for rapid and earlier deployment. By relaxing oversight for tools where clinicians can independently review the analysis and output recommendations, FDA is signaling support for innovation in ambient intelligence, predictive analytics, and patient-centric digital health applications.

And we do not expect FDA to be done. It has signaled its intention to streamline its guidance regarding software and AI in medical devices, with additional guidance having been removed earlier this year. Indeed, FDA's Center for Devices and Radiological Health's 2026 guidance priorities include finalizing the Predetermined Change Control Plans for Medical Devices guidance, Policy for Device Software Functions, and advancing new frameworks for real-world performance evaluation that are yet to come. These efforts reflect a regulatory posture that sees AI as essential to health care delivery, and that aims to build modern guardrails to enable safe, trustworthy scaling.

Looking ahead, the health care ecosystem will increasingly depend on AI to enhance quality, reduce burden, and expand access. FDA's evolving guidance framework shows it is preparing the runway, and encouraging innovation while reinforcing patient and user trust. The organizations that succeed in 2026 will be those that innovate boldly, govern thoughtfully, and embrace AI as the backbone of tomorrow's health care system.